Morphine Milligram Equivalents: Why a Dose Is Not a Diagnosis

A fifty-eight-year-old man with arachnoiditis kept a warehouse job for six years on a stable dose. Then a quality report flagged his physician’s practice, his dose was halved within eight weeks, and by week nine he was in an emergency room in withdrawal. One figure had steered every decision about him, a total in morphine milligram equivalents, and nothing on his chart described what was generating his pain.

The video above, A Dose Is Not a Diagnosis, is Chapter 17 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD. Below: how the unit is calculated, why it is unstable, and what the tapering research shows on both sides.

What morphine milligram equivalents are meant to measure

A morphine milligram equivalent, or MME, converts each opioid into one morphine-sized figure so that different drugs can be added into a daily total. Risk does rise with dose. In a Washington health plan cohort of 9,940 patients on opioids for chronic pain, published in 2010, those taking 100 milligrams or more a day had 8.9 times the overdose rate of those taking 1 to 20.

Read the same study for its absolute numbers and the picture shifts. The yearly overdose rate was 0.2 percent at the low dose and 1.8 percent at the high dose. Only 1.8 percent of the observation time was spent at 100 milligrams or more, and the authors wrote that most overdoses happened on low to moderate regimens. When the dose studies were later pooled, overdose risk began climbing at 20 milligrams a day. There is no cliff at 90. There is a ramp that begins with the first tablet.

How a voluntary sentence became a pharmacy alert

The 2016 federal guideline told clinicians to avoid raising doses to 90 MME or more, or to justify it carefully. It said patients already above that line should be offered a chance to reevaluate, and it called its recommendations voluntary. Then bodies with no patients took the wheel. A quality-measurement organization turned the sentence into a health-plan score in which a lower rate counts as better performance, after lowering its own line from 120 to 90 in 2019. Medicare told drug plans to install a pharmacy-counter edit at 90. By mid-2017, 22 states had some kind of dose-threshold policy, with lines set anywhere from 30 to 300 milligrams.

That spread tells you the line is not a biological constant. Medicare’s own record also shows what happened when a hard stop sat at 200: 93 percent of beneficiaries who hit it requested a coverage determination, and most were approved. The edit found paperwork, not dangerous patients, and a plan scored on a percentage has every economic reason to move the percentage, whatever happens to the person inside it.

A unit that clinicians cannot agree on

When 319 clinicians converted identical doses, a 75-microgram fentanyl patch came out at an average of 176 milligrams, give or take 117, and 40 milligrams of methadone at 193, give or take 201. Eight online calculators disagreed on one dose by anywhere from minus 55 percent to plus 242 percent. Only 27 percent of published studies state which conversion they used, and four defensible definitions of a daily dose moved the share of high-dose patients in one state’s data from 5.9 to 14.2 percent.

Then the milligram enters a body. The liver enzyme CYP2D6 turns codeine and tramadol into their active form. Poor metabolizers get 96 percent less morphine from a codeine dose, while ultrarapid metabolizers get 45 percent more. After knee and hip replacement, the effect of an opioid receptor gene on morphine requirement reversed direction depending on whether the patient had diabetes. Enzymes set how much drug a tablet becomes, and the insulin behind diabetes changes what that drug does once it arrives.

Dose is a weak predictor of overdose

In a Medicare cohort, dose-based safety measures identified 29.29 percent of the people who later overdosed. A model using dose plus 267 other variables identified 90 percent. Dose was the strongest single predictor and still only one of 268. Among patients starting a first prescription, a substance-use disorder raised overdose risk 2.74-fold and age over 75 raised it 3.22-fold. Adding a benzodiazepine raised the hazard 5.05-fold in the first 90 days.

What tapering did, and what it did not do

The evidence runs in both directions, and both deserve a hearing. Among 1,394,102 veterans, those treated longest had a hazard of 6.77 for death by overdose or suicide after their opioids were stopped. Monthly reductions faster than 30 percent carried a hazard of 5.33 for overdose the next month, while reductions of 10 percent or less carried none. For stable patients in a trial emulation, eleven-month overdose or suicide risk ran 0.96 percent when nothing changed, 1.10 percent after a taper and 1.28 percent after an abrupt stop.

On the other side, Oregon Medicaid patients had lower overdose risk after discontinuation, and in Australia, stopping was linked with lower fatal overdose and no change in suicide. Taken together, the danger does not live in the milligram. It lives in how the change is made: its speed, the loss of a physician, the absence of a plan. When a simulated patient on a stable dose phoned primary-care clinics, 40.7 percent said they would not prescribe. The damage from rushed, unsupported cuts is laid out in why abrupt opioid tapering is also harm, and the mortality data that frame it are in what the death data show about chronic pain.

The strongest case for strict limits

Prescribing per person peaked in 2010 at 782 MME and in 2015 was still three times the 1999 level. Deaths have fallen, from 110,037 in 2023 to 69,973 in 2025. Prescribing was too high, and a physician who dismisses that is not being honest either.

The rest of the record matters as much. In 2023, deaths from prescription-type opioids ran 2.9 per 100,000 against 22.2 for illicit synthetics. Across 32 states, prescribing-cap laws changed neither prescribing nor overdose. The risk also moved sideways: gabapentin was detected in 9.7 percent of overdose deaths across 23 states,. The rules worked mostly on people who already had a prescription.

Treat the generator so the dose can fall

The way out is not to win the argument about the number. It is to remove the reason for it. In 191 English primary-care practices, a voluntary group program with a year of nurse and lay support got 29 percent of participants off opioids against 7 percent with usual care, and pain interference did not worsen. Where the veterans’ system required an interdisciplinary case review instead of a cut, discontinuation fell 11.16 percentage points and all-cause mortality fell 3.31. Keeping the patient in care is itself a treatment.

For this man, diagnostic blocks were positive at two facet joints and the sacroiliac joint, which is how medial branch blocks and ablation are supposed to work: prove the generator, then treat it. Ablation followed, done awake. So did the unglamorous part. His fasting insulin was 31 and a sleep study found apnea, so he changed how he ate and started walking. That work targets the insulin that changes what a milligram does and the sleep an opioid’s effect depends on. Over eleven months, by his choice and at his pace, his dose settled at 40 milligrams. Arachnoiditis does not go away, and the goal was never zero. How blocks prove a joint is the source is covered in the post on diagnostic blocks.

In my practice, arriving patients average above 90 MME a day. Under interventional treatment, 21 percent of them are fully off opioids within 90 days and 34 percent within a year, and under 1 percent of the established population stays above 90. These are practice-reported figures from our own population, not trial outcomes, and individual results vary. What the cheapest treatment really costs is the subject of the four-dollar bottle post. The evidence behind every figure, graded honestly, is in the Chapter 17 technical supplement.

Frequently asked questions

What does MME mean on a prescription record?

MME stands for morphine milligram equivalents. It converts each opioid into the amount of morphine thought to have a similar effect, so different drugs can be summed into one daily total. The conversion is less exact than it looks, since clinicians given identical doses produced very different answers, and buprenorphine should not be counted in the total at all. Sedatives taken alongside often matter more, which is why we ask patients to come off one of them.

Is 90 MME a dangerous dose?

Risk rises with dose, but as a slope rather than a step. Pooled dose studies found overdose risk starting to climb at 20 milligrams a day, and the 2016 guideline described 90 as a line to avoid crossing or to justify, not an order to cut established patients. How dose changes fit into a larger plan is explained in medication as a bridge during opioid tapering.

Do dosage thresholds require a physician to lower a stable dose?

The agencies that wrote them say no. Federal clinician guidance warns against misreading cautionary thresholds as mandates for dose reduction, and Medicare says its pharmacy edits should not act as a prescribing limit or a substitute for clinical judgment. Access still suffered: 40.7 percent of clinics called by a simulated patient on a stable dose said they would not prescribe. That access gap is documented in research on patients who struggle to find a new physician.

How fast is too fast when a dose is reduced?

For people on long-term opioids, cutting more than 30 percent in a month was tied to a 5.33 hazard of overdose the next month; cuts of 10 percent or less showed no added hazard. Any change belongs in a written plan with your prescribing physician, including who decides when to pause. Untreated metabolic drivers can keep pain high and make any plan harder, as explained in how high insulin makes you hurt.

Are non-opioid pain relievers automatically safer?

Substitution is a trade. In the year after the 2016 guideline, prescriptions for non-opioid pain drugs ran above the prior trend, gabapentin turned up in 9.7 percent of overdose deaths across 23 states, and ketorolac carried an odds ratio of 20.67 for gastrointestinal bleeding. Every alternative has its own risks to weigh with your physician. For the stomach, see what long-term NSAIDs do to the gut.

Sources

1. Dunn, K. M., Saunders, K. W., Rutter, C. M., Banta-Green, C. J., Merrill, J. O., Sullivan, M. D., Weisner, C. M., Silverberg, M. J., Campbell, C. I., Psaty, B. M., & Von Korff, M. (2010). Opioid prescriptions for chronic pain and overdose: a cohort study. Annals of Internal Medicine, 152(2), 85–92. https://doi.org/10.7326/0003-4819-152-2-201001190-00006
2. Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC Guideline for Prescribing Opioids for Chronic Pain–United States, 2016. JAMA, 315(15), 1624–1645. https://doi.org/10.1001/jama.2016.1464
3. Rennick, A., Atkinson, T., Cimino, N. M., Strassels, S. A., McPherson, M. L., & Fudin, J. (2016). Variability in Opioid Equivalence Calculations. Pain Medicine, 17(5), 892–898. https://doi.org/10.1111/pme.12920
4. Crews, K. R., Monte, A. A., Huddart, R., Caudle, K. E., Kharasch, E. D., Gaedigk, A., Dunnenberger, H. M., Leeder, J. S., Callaghan, J. T., Samer, C. F., Klein, T. E., Haidar, C. E., Van Driest, S. L., Ruano, G., Sangkuhl, K., Cavallari, L. H., Müller, D. J., Prows, C. A., Nagy, M., … Skaar, T. C. (2021). Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clinical Pharmacology and Therapeutics, 110(4), 888–896. https://doi.org/10.1002/cpt.2149
5. Lo-Ciganic, W.-H., Huang, J. L., Zhang, H. H., Weiss, J. C., Wu, Y., Kwoh, C. K., Donohue, J. M., Cochran, G., Gordon, A. J., Malone, D. C., Kuza, C. C., & Gellad, W. F. (2019). Evaluation of Machine-Learning Algorithms for Predicting Opioid Overdose Risk Among Medicare Beneficiaries With Opioid Prescriptions. JAMA Network Open, 2(3), e190968. https://doi.org/10.1001/jamanetworkopen.2019.0968
6. Oliva, E. M., Bowe, T., Manhapra, A., Kertesz, S., Hah, J. M., Henderson, P., Robinson, A., Paik, M., Sandbrink, F., Gordon, A. J., & Trafton, J. A. (2020). Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ, 368, m283. https://doi.org/10.1136/bmj.m283
7. Glanz, J. M., Xu, S., Narwaney, K. J., McClure, D. L., Rinehart, D. J., Ford, M. A., Nguyen, A. P., & Binswanger, I. A. (2023). Association Between Opioid Dose Reduction Rates and Overdose Among Patients Prescribed Long-Term Opioid Therapy. Substance Abuse, 44(3), 209–219. https://doi.org/10.1177/08897077231186216
8. Larochelle, M. R., Lodi, S., Yan, S., Clothier, B. A., Goldsmith, E. S., & Bohnert, A. S. B. (2022). Comparative Effectiveness of Opioid Tapering or Abrupt Discontinuation vs No Dosage Change for Opioid Overdose or Suicide for Patients Receiving Stable Long-term Opioid Therapy. JAMA Netw Open, 5(8), e2226523. https://doi.org/10.1001/jamanetworkopen.2022.26523
9. Sandhu, H. K., Booth, K., Furlan, A. D., Shaw, J., Carnes, D., Taylor, S. J. C., Abraham, C., Alleyne, S., Balasubramanian, S., Betteley, L., Haywood, K. L., Iglesias-Urrutia, C. P., Krishnan, S., Lall, R., Manca, A., Mistry, D., Newton, S., Noyes, J., Nichols, V., … Underwood, M. (2023). Reducing Opioid Use for Chronic Pain With a Group-Based Intervention: A Randomized Clinical Trial. JAMA, 329(20), 1745–1756. https://doi.org/10.1001/jama.2023.6454
10. Li, Y., Barr, K. D., Trafton, J. A., Oliva, E. M., Garrido, M. M., Frakt, A. B., & Strombotne, K. L. (2023). Impact of Mandated Case Review Policy on Opioid Discontinuation and Mortality Among High-Risk Long-Term Opioid Therapy Patients: The STORM Stepped-Wedge Cluster Randomized Controlled Trial. Subst Abus, 44(4), 292–300. https://doi.org/10.1177/08897077231198299

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 17 of The Pained Brain by Dr. Padda and Dr. KrisJay Fucanan, MD. Last reviewed September 2026.

Dr. Gurpreet Singh Padda, MD, MBA, MHP